Elizabeth Masson-Hurlburt - May 21, 2021 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
EVP, Head of Clinical Ops
Signature
/s/ Elizabeth Masson-Hurlburt
Stock symbol
CRMD
Transactions as of
May 21, 2021
Transactions value $
-$55,394
Form type
4
Date filed
5/25/2021, 04:46 PM
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRMD Common Stock Sale -$55.4K -8K -100% $6.92 0 May 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CRMD Stock Option (Right to Buy Common Stock) 140K May 21, 2021 Common Stock 140K $8.32 Direct F2
holding CRMD Stock Option (Right to Buy Common Stock) 37.5K May 21, 2021 Common Stock 37.5K $5.63 Direct F3
holding CRMD Stock Option (Right to Buy Common Stock) 37.5K May 21, 2021 Common Stock 37.5K $4.08 Direct F3
holding CRMD Stock Option (Right to Buy Common Stock) 24.8K May 21, 2021 Common Stock 24.8K $5.63 Direct F4
holding CRMD Stock Option (Right to Buy Common Stock) 20.9K May 21, 2021 Common Stock 20.9K $8.30 Direct F5
holding CRMD Stock Option (Right to Buy Common Stock) 54K May 21, 2021 Common Stock 54K $1.45 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $6.665 to $6.97. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones.
F3 These options were granted on 05/11/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F4 These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F5 These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase 2,100 shares that are subject to vesting each on January 10, 2021 and January 10, 2022.
F6 The options vest as follows: 37,200 will vest over four years in four (4) equal installments on the first four anniversaries of 3/19/2018. The remaining options vest on the achievement of certain milestones, subject to continued employment.

Remarks:

The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.